Business
Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements
Generated full-year 2025 net product sales of XDEMVY® of $451.4 million, an increase of more than 150% year-over-year Providing expected XDEMVY peak sales potential of more than $2 billion Extending category-creating leadership with initiation of Phase 2 trial of TP-04 in ocular rosacea (OR) and plans to initiate a Phase 2 trial of TP-05 for Lyme disease prevention in Q2 2026 Management to host conference call today, February 23, 2026, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., Feb. 23, 2026
About this update from Tarsus Pharmaceuticals, Inc.
[{"type":"image","alt":"Tarsus Pharmaceuticals, Inc","displaySize":"","headline":null,"caption":"Tarsus Pharmaceuticals, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":218,"url":"https://media.zenfs.com/en/globenewswire.com/4482918fc3608261626e37d219861c79"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YAv_H0H0DM_L1x1BaB8NHg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4482918fc3608261626e37d219861c79","width":300,"height":218}},"lazy":false},{"type":"text","content":"Generated full-year 2025 net product sales of XDEMVY® of $451.4 million, an increase of more than 150% year-over-year","length":122,"tagName":"p"},{"type":"text","content":"Providing expected XDEMVY peak sales potential of more than $2 billion","length":70,"tagName":"p"},{"type":"text","content":"Extending category-creating leadership with initiation of Phase 2 trial of TP-04 in ocular rosacea (OR) and plans to initiate a Phase 2 trial of TP-05 for Lyme disease prevention in Q2 2026","length":189,"tagName":"p"},{"type":"text","content":"Management to host conference call today, February 23, 2026, at 1:30 p.m. PT / 4:30 p.m. ET","length":96,"tagName":"p"},{"type":"text","content":"IRVINE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced financial results for the fourth quarter and full-year ended December 31, 2025, and recent business achievements.","length":229,"tagName":"p"},{"type":"text","content":"“XDEMVY has driven a fundamental shift in eye care,” said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. “In just two years, we have built broad access, changed how physicians treat, and established a durable and growing franchise, giving us confidence in a clear potential path to peak sales exceeding $2 billion. Importantly, XDEMVY validates our disciplined model for category creation - integrating science, commercial execution, and strategic investment. We are now applying that proven framework across our pipeline in ocular rosacea and Lyme disease prevention with the goal of establishing additional new standards of care.”","length":661,"tagName":"p"},{"type":"text","content":"Recent Business Highlights and Corporate Update","length":47,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text",...